Authorized purpose: Overjet Caries Assist is a concurrent-read aid for detecting and segmenting caries on bitewing radiographs of permanent dentition in patients aged 18 years and older; it provides additional information for a dentist and is not a replacement for complete review or clinical judgment.
Clinical role
Concurrent-read detection, localization, segmentation, and review support for labeled dental radiographs.
Images and patients
X-ray/Radiography · Permanent dentition; tooth surfaces and caries
Key limitation
Keep in mind: Use is limited to bitewing radiographs of permanent dentition in patients aged 18 years and older; the labeling warns of false positives and negatives and states the system is not 100% sensitive.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Overjet Caries Assist is a concurrent-read aid for detecting and segmenting caries on bitewing radiographs of permanent dentition in patients aged 18 years and older; it provides additional information for a dentist and is not a replacement for complete review or clinical judgment.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Permanent dentition; tooth surfaces and caries Input: Supported intraoral, bitewing, or periapical radiographs.
Who uses it?Intended users: Trained and licensed dentists.
What does the software produce?Output: Candidate dental findings, localized regions, segmentations, and review displays.
What is its most important limitation?Key limitation: Use is limited to bitewing radiographs of permanent dentition in patients aged 18 years and older; the labeling warns of false positives and negatives and states the system is not 100% sensitive.
Clinical takeaway. Clinical role: Overjet Caries Assist is a concurrent-read aid for detecting and segmenting caries on bitewing radiographs of permanent dentition in patients aged 18 years and older; it provides additional information for a dentist and is not a replacement for complete review or clinical judgment.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone testing on 352 images, summarized per surface (7,129 surfaces): overall sensitivity 72.0% (62.9%, 81.1%) and specificity 98.1% (97.7%, 98.5%). In a multi reader fully crossed study, 13 US licensed dentists read 352 radiographs (104 containing caries / 248 without caries) against consensus ground truth of three US licensed dentists; overall reader sensitivity improved from 57.9% (48.9%, 66.0%) to 76.2% (68.4%, 82.6%), and weighted AFROC AUC increased by 0.057 (0.039, 0.098). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Overjet Caries Assist is a concurrent-read aid for detecting and segmenting caries on bitewing radiographs of permanent dentition in patients aged 18 years and older; it provides additional information for a dentist and is not a replacement for complete review or clinical judgment.
Use is limited to bitewing radiographs of permanent dentition in patients aged 18 years and older; the labeling warns of false positives and negatives and states the system is not 100% sensitive.
The exact FDA document reports standalone testing on 352 images, summarized per surface (7,129 surfaces): overall sensitivity 72.0% (62.9%, 81.1%) and specificity 98.1% (97.7%, 98.5%). In a multi reader fully crossed study, 13 US licensed dentists read 352 radiographs (104 containing caries / 248 without caries) against consensus ground truth of three US licensed dentists; overall reader sensitivity improved from 57.9% (48.9%, 66.0%) to 76.2% (68.4%, 82.6%), and weighted AFROC AUC increased by 0.057 (0.039, 0.098). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Standalone performance of the Overjet AI algorithm for the 352 images is shown in the tables below. Sensitivity and specificity were summarized based on surfaces, and 95% CIs were provided" … "A total of 7,129 surfaces were available and included in the analysis.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports standalone testing on 352 images, summarized per surface (7,129 surfaces): overall sensitivity 72.0% (62.9%, 81.1%) and specificity 98.1% (97.7%, 98.5%). In a multi reader fully crossed study, 13 US licensed dentists read 352 radiographs (104 containing caries / 248 without caries) against consensus ground truth of three US licensed dentists; overall reader sensitivity improved from 57.9% (48.9%, 66.0%) to 76.2% (68.4%, 82.6%), and weighted AFROC AUC increased by 0.057 (0.039, 0.098). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Standalone performance of the Overjet AI algorithm for the 352 images is shown in the tables below. Sensitivity and specificity were summarized based on surfaces, and 95% CIs were provided" … "A total of 7,129 surfaces were available and included in the analysis.". Read from the exact FDA decision document on 2026-11-14.
Standalone per-surface sensitivity for caries on 352 images (7,129 surfaces): overall 72.0% (95% CI 62.9%-81.1%); primary caries 74.4% (95% CI 64.4%-84.4%); secondary caries 62.5% (95% CI 46.6%-78.4%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Standalone performance of the Overjet AI algorithm for the 352 images is shown in the tables below. Sensitivity and specificity were summarized based on surfaces, and 95% CIs were provided" … "A total of 7,129 surfaces were available and included in the analysis.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone per-surface specificity for caries on 352 images (7,129 surfaces): overall 98.1% (95% CI 97.7%-98.5%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Standalone performance of the Overjet AI algorithm for the 352 images is shown in the tables below. Sensitivity and specificity were summarized based on surfaces, and 95% CIs were provided" … "A total of 7,129 surfaces were available and included in the analysis.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K212519 FDA evidence package for Overjet Caries Assist
DesignFDA 510(k) or PMA decision evidence and product verification described in the exact submission.
PopulationPermanent dentition; tooth surfaces and caries
Scopeexact submission
Tested versionOverjet Caries Assist configuration described in K212519
IndependenceSponsor or vendor study
K212519
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K212519 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported intraoral, bitewing, or periapical radiographs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes supported dental radiograph systems and images with minimum resolution of 500 by 500 pixels; the complete local interface contract remains unverified.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Overjet Caries Assist as a cloud native application on a web platform (Edge, Chrome, Firefox) for any operating system, with images pulled in from a clinic or dental office and results pushed to a dashboard. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Logicon is a local software while Overjet Caries Assist is a cloud native application." … "Platform Windows PC Web - Edge, Chrome, Firefox OS Microsoft Window 7, 8, 10 Any". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Overjet Caries Assist as a cloud native application on a web platform (Edge, Chrome, Firefox) for any operating system, with images pulled in from a clinic or dental office and results pushed to a dashboard. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Logicon is a local software while Overjet Caries Assist is a cloud native application." … "Platform Windows PC Web - Edge, Chrome, Firefox OS Microsoft Window 7, 8, 10 Any". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA package describes supported dental radiograph systems and images with minimum resolution of 500 by 500 pixels; the complete local interface contract remains unverified.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Overjet's trust center states a completed independent HITRUST audit and certification, HIPAA business associate compliance, GDPR and CCPA alignment, third-party penetration tests, need-to-know data access and employee security training. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Only trained and licensed dentists should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K212519 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to bitewing radiographs of permanent dentition in patients aged 18 years and older; the labeling warns of false positives and negatives and states the system is not 100% sensitive.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package describes supported dental radiograph systems and images with minimum resolution of 500 by 500 pixels; the complete local interface contract remains unverified.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to bitewing radiographs of permanent dentition in patients aged 18 years and older; the labeling warns of false positives and negatives and states the system is not 100% sensitive.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K212519 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to bitewing radiographs of permanent dentition in patients aged 18 years and older; the labeling warns of false positives and negatives and states the system is not 100% sensitive.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. dental radiograph analysis software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
14Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.
Authorized purpose: Acts as a CADe second reader to detect and segment caries on periapical radiographs of permanent teeth in patients aged 12 years and older; clinicians review the contours and percentage analysis in context.
Authorized purpose: Aids dentists reviewing bitewing and periapical radiographs of permanent teeth by detecting/segmenting caries and periapical radiolucencies, identifying restorations and dental anatomy, and measuring mesial/distal bone levels; it does not replace dentist review.
Authorized purpose: Aid dentists in detecting and segmenting caries on bitewing and periapical radiographs for patients aged 4-11 with primary or permanent teeth; the output is additional information and does not replace a complete dental review or clinical judgment.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.